Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gain Therapeutics, Inc.GANX · Entity 6943 | Director · Chief Executive Officer | March 26, 2024 | March 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gain Therapeutics, Inc.
Report date March 26, 2024 · Filed March 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,140 |
Ending reported balance
After 2024-03-26 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-03-26 · Exercise / conversion · Acquired 18,750 · Balance 25,763 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Row 2 · 2024-03-26 · Exercise / conversion · Acquired 825 · Balance 26,588 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Row 3 · 2024-03-26 · Exercise / conversion · Acquired 637 · Balance 27,225 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Row 4 · 2024-03-26 · Tax withholding · Disposed 6,085 · Balance 21,140 F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 56,250 |
Reported balance
After 2024-03-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-26 · Exercise / conversion · Disposed 18,750 · Balance 56,250 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3: The RSUs vested 25% on the one-year anniversary of the grant date and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,250 |
Reported balance
After 2024-03-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-03-26 · Exercise / conversion · Disposed 825 · Balance 8,250 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4: The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,376 |
Reported balance
After 2024-03-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-26 · Exercise / conversion · Disposed 637 · Balance 6,376 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3: The RSUs vested 25% on the one-year anniversary of the grant date and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3: The RSUs vested 25% on the one-year anniversary of the grant date and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
F4: The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sucampo Pharmaceuticals, Inc.
Report date June 30, 2017 · Filed July 07, 2017
Section 16 reporting ended · disclosed 2017-07-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Class A (ESPP)SEC Table I · non-derivative | Direct | 4,763 |
Reported balance
After 2017-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-06-30 · Grant · Acquired 673 · Balance 4,763 F1: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16(b)-3(c). F2: In accordance with the ESPP, these shares were purchased at 85% of the June 30, 2017 closing price of the issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16(b)-3(c).
F2: In accordance with the ESPP, these shares were purchased at 85% of the June 30, 2017 closing price of the issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 26, 2024 Filed Mar 29, 2024 01:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionRestricted Stock Units · Derivative | 637 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-011836 · ownership.xml · derivative · entry 7 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,376 Underlying: Common Stock · 192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs vested 25% on the one-year anniversary of the grant date and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs vested 25% on the one-year anniversary of the grant date and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 26, 2024 Filed Mar 29, 2024 01:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionRestricted Stock Units · Derivative | 825 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-011836 · ownership.xml · derivative · entry 6 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 249 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F4 · derivative.expiration_date: The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 26, 2024 Filed Mar 29, 2024 01:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-011836 · ownership.xml · derivative · entry 5 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs vested 25% on the one-year anniversary of the grant date and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs vested 25% on the one-year anniversary of the grant date and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 26, 2024 Filed Mar 29, 2024 01:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Tax withholdingCommon Stock | 6,085 | $4.06 | $24,705.10 |
DisclosureSEC source: 0001493152-24-011836 · ownership.xml · nonDerivative · entry 4 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,140 F2 · acquired: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. Read SEC document |
| March 26, 2024 Filed Mar 29, 2024 01:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionCommon Stock | 637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-011836 · ownership.xml · nonDerivative · entry 3 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 26, 2024 Filed Mar 29, 2024 01:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionCommon Stock | 825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-011836 · ownership.xml · nonDerivative · entry 2 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 26, 2024 Filed Mar 29, 2024 01:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionCommon Stock | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-011836 · ownership.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 01:30 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 370,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001493152-24-011215 · ownership.xml · derivative · entry 1 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,000 Underlying: Common Stock · 370,000 shares Expires 2034-03-21 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on March 21, 2025 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 21:17 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | SaleCommon Stock | 206 | $2.46 | $506.76 |
DisclosureSEC source: 0001209191-23-059558 · doc4.xml · nonDerivative · entry 2 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,286 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4602 to $2.485 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 21:17 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionRestricted Stock Units · Derivative | 637 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059558 · doc4.xml · derivative · entry 3 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,013 Underlying: Common Stock · 637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs vested 25% on September 20, 2023 and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs vested 25% on September 20, 2023 and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 21:17 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionCommon Stock | 637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-059558 · doc4.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| December 07, 2023 Filed Dec 14, 2023 21:01 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | SaleCommon Stock | 1,820 | $2.50 | $4,550.00 |
DisclosureSEC source: 0001104659-23-126020 · tm2332941-1_4seq1.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,855 F1 · shares: Reflects shares sold to cover withholding taxes incurred upon the vesting and settlement of restricted stock units in a trade that was initiated by the Issuer on the Reporting Person's behalf. F2 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.48 to $2.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range specified in this footnote. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:36 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionRestricted Stock Units · Derivative | 825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051502 · doc4.xml · derivative · entry 2 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,075 Underlying: Common Stock · 825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F2 · derivative.expiration_date: The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:36 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionCommon Stock | 825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-051502 · doc4.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 20:34 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionRestricted Stock Units · Derivative | 2,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050379 · doc4.xml · derivative · entry 2 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,650 Underlying: Common Stock · 2,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The RSUs vested 25% on September 20, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F2 · derivative.expiration_date: The RSUs vested 25% on September 20, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 20:34 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionCommon Stock | 2,550 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-050379 · doc4.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:18 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionRestricted Stock Units · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041027 · doc4.xml · derivative · entry 2 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,900 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F2 · derivative.expiration_date: The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:18 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | Exercise / conversionCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-041027 · doc4.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 21:26 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021257 · doc4.xml · derivative · entry 2 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs shall vest 25% on March 23, 2024 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 21:26 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001209191-23-021257 · doc4.xml · derivative · entry 1 Alder Matthias · CIK 0001370820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-03-23 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on March 23, 2024 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantRestricted Stock Units · Derivative | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051003 · doc4.xml · derivative · entry 2 Alder Matthias · CIK 0001370820 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,200 Underlying: Common Stock · 10,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs shall vest 25% on September 20, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs shall vest 25% on September 20, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 60,900 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-22-051003 · doc4.xml · derivative · entry 1 Alder Matthias · CIK 0001370820 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,900 Underlying: Common Stock · 60,900 shares Expires 2032-09-20 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on September 20, 2023 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:36 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantRestricted Stock Units · Derivative | 13,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042571 · doc4.xml · derivative · entry 2 Alder Matthias · CIK 0001370820 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs shall vest 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs shall vest 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:36 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 79,200 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001209191-22-042571 · doc4.xml · derivative · entry 1 Alder Matthias · CIK 0001370820 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,200 Underlying: Common Stock · 79,200 shares Expires 2032-07-15 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on July 1, 2023 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:30 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantNon Qualified Stock Option (right to buy) · Derivative | 200,000 | $5.86 Strike: $5.86 | $1,172,000.00 |
DisclosureSEC source: 0001415889-21-006258 · form4-12282021_041202.xml · derivative · entry 1 Alder Matthias · CIK 0001370820 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-10-15 F1 · derivative.exercise_date: 50,000 options shall vest on 10/15/2022 (the "Initial Vesting Date") and the remaining 150,000 options shall vest in a series of thirty-six (36) successive equal monthly installments on each subsequent monthly anniversary of the Initial Vesting Date. Read SEC document |
| June 30, 2017 Filed Jul 7, 2017 16:30 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A (ESPP) | 673 | $8.93 | $6,009.89 |
DisclosureSEC source: 0001171843-17-003999 · formfour.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · EVP, Gen. Council & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,763 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the June 30, 2017 closing price of the issuer's common stock. Read SEC document |
| March 31, 2017 Filed May 10, 2017 16:01 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A (ESPP) | 641 | $9.35 | $5,993.35 |
DisclosureSEC source: 0001171843-17-002917 · formfour.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · EVP, Gen. Council & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,224 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period January 1, 2017 through March 31, 2017. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the March 31, 2017 closing price of the issuer's common stock. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 17:01 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantEmployee Stock Option (right to buy) · Derivative | 63,000 | $0.00 Strike: $11.85 | $0.00 |
DisclosureSEC source: 0001171843-17-001360 · f4_alder030817.xml · derivative · entry 2 Alder Matthias · CIK 0001370820 · EVP, Bus.Dev.&Lic., GC & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,500 Underlying: Class A Common Stock · 63,000 shares Expires 2027-03-02 F2 · derivative.exercise_date: The option will vest over a four-year period, with 25% vesting on March 2, 2018 and the remaining 75% vesting in equal monthly increments over the three-year period thereafter. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 17:01 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-001360 · f4_alder030817.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · EVP, Bus.Dev.&Lic., GC & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F1 · security: Common stock granted consists of restricted stock units that vest on March 2, 2020. Read SEC document |
| December 31, 2016 Filed Jan 6, 2017 16:01 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A (ESPP) | 134 | $10.46 | $1,401.64 |
DisclosureSEC source: 0001171843-17-000122 · formfour.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,583 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2016 through December 31, 2016. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the September 30, 2016 closing price of the issuer's common stock. Read SEC document |
| November 28, 2016 Filed Nov 28, 2016 21:30 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,975 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001171843-16-013396 · f4_alder112816.xml · derivative · entry 9 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Class A Common Stock · 24,975 shares Expires 2024-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 62,996 options became exercisable on 10/27/15, and 62,996 options became exercisable on 10/27/16. Read SEC document |
| November 28, 2016 Filed Nov 28, 2016 21:30 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | SaleCommon Stock, Class A | 24,975 | $16.73 | $417,831.75 |
DisclosureSEC source: 0001171843-16-013396 · f4_alder112816.xml · nonDerivative · entry 6 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,449 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.15 to $17.45, inclusive. The reporting person will, upon request, provide Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 28, 2016 Filed Nov 28, 2016 21:30 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Exercise / conversionCommon Stock, Class A | 24,975 | $8.33 | $208,041.75 |
DisclosureSEC source: 0001171843-16-013396 · f4_alder112816.xml · nonDerivative · entry 5 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2016 Filed Nov 28, 2016 21:30 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 99,025 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001171843-16-013396 · f4_alder112816.xml · derivative · entry 8 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,475 Underlying: Class A Common Stock · 99,025 shares Expires 2024-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 62,996 options became exercisable on 10/27/15, and 62,996 options became exercisable on 10/27/16. Read SEC document |
| November 25, 2016 Filed Nov 28, 2016 21:30 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | SaleCommon Stock, Class A | 99,025 | $15.88 | $1,572,517.00 |
DisclosureSEC source: 0001171843-16-013396 · f4_alder112816.xml · nonDerivative · entry 4 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,449 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $16.20, inclusive. The reporting person will, upon request, provide Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 25, 2016 Filed Nov 28, 2016 21:30 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Exercise / conversionCommon Stock, Class A | 99,025 | $8.33 | $824,878.25 |
DisclosureSEC source: 0001171843-16-013396 · f4_alder112816.xml · nonDerivative · entry 3 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 21:30 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001171843-16-013396 · f4_alder112816.xml · derivative · entry 7 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,500 Underlying: Class A Common Stock · 26,000 shares Expires 2024-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 62,996 options became exercisable on 10/27/15, and 62,996 options became exercisable on 10/27/16. Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 21:30 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | SaleCommon Stock, Class A | 26,000 | $15.77 | $410,020.00 |
DisclosureSEC source: 0001171843-16-013396 · f4_alder112816.xml · nonDerivative · entry 2 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,449 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.65 to $15.88, inclusive. The reporting person will, upon request, provide Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 21:30 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Exercise / conversionCommon Stock, Class A | 26,000 | $8.33 | $216,580.00 |
DisclosureSEC source: 0001171843-16-013396 · f4_alder112816.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 21, 2016 16:05 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock, Class A (ESPP) | 639 | $9.38 | $5,993.82 |
DisclosureSEC source: 0001171843-16-012572 · f4_alder102116.xml · nonDerivative · entry 1 Alder Matthias · CIK 0001370820 · EVP, Bus. Dev.&Lic, G.C. &Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,449 F1 · security: The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2016 through September 30, 2016. This transaction is exempt under Rule 16(b)-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at 85% of the July 1, 2016 closing price of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.